The MINDACT trial: the first prospective clinical validation of a genomic tool.
One of the main challenges in oncology today has become to distinguish accurately between those patients who need adjuvant treatment and those who do not. This, together with the identification of the best type of therapy for the individual patient and the development of drugs targeting specific characteristics of tumour cells, are the goals of treatment tailoring or personalized medicine. The MINDACT trial (Microarray In Node negative Disease may Avoid ChemoTherapy) was recently launched with the aim of prospectively validating the superior performance of a new prognostic RNA-based tool--the Amsterdam 70-gene profiler MammaPrint, in order to implement its use in clinical practice later on. This manuscript shortly reviews the rational, design and logistics of MINDACT.
Cardoso
Fatima
F
Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium. fatima.cardoso@bordet.be
Piccart-Gebhart
Martine
M
Van't Veer
Laura
L
Rutgers
Emiel
E
D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D020869:Gene Expression Profiling; D023281:Genomics / Q000295:instrumentation*; D006801:Humans; D015337:Multicenter Studies as Topic; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012107:Research Design